← Back to Screener
Vanda Pharmaceuticals Inc. (VNDA)
Price$7.16
Favorite Metrics
Price vs S&P 500 (26W)29.16%
Price vs S&P 500 (4W)-20.89%
Market Capitalization$421.74M
All Metrics
Book Value / Share (Quarterly)$5.54
P/TBV (Annual)2.48x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-5.29%
Cash Flow / Share (Quarterly)$-1.87
Price vs S&P 500 (YTD)-20.22%
Gross Margin (TTM)93.96%
Net Profit Margin (TTM)-102.02%
EPS (TTM)$-3.74
10-Day Avg Trading Volume1.03M
EPS Excl Extra (TTM)$-3.74
Revenue Growth (5Y)-2.73%
EPS (Annual)$-3.74
ROI (Annual)-65.88%
Gross Margin (Annual)93.96%
Net Profit Margin (5Y Avg)-19.08%
Cash / Share (Quarterly)$4.46
Revenue Growth QoQ (YoY)7.58%
ROA (Last FY)-45.09%
Revenue Growth TTM (YoY)8.72%
EBITD / Share (TTM)$-2.23
ROE (5Y Avg)-12.53%
Operating Margin (TTM)-69.95%
Cash Flow / Share (Annual)$-1.87
P/B Ratio1.29x
P/B Ratio (Quarterly)1.59x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.59x
ROA (TTM)-37.58%
EV / EBITDA (TTM)40.84x
EPS Incl Extra (Annual)$-3.74
Current Ratio (Annual)2.39x
Quick Ratio (Quarterly)2.19x
3-Month Avg Trading Volume2.53M
52-Week Price Return66.74%
EV / Free Cash Flow (Annual)-31.46x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.55
P/S Ratio (Annual)1.95x
Asset Turnover (Annual)0.44x
52-Week High$9.94
Operating Margin (5Y Avg)-15.89%
EPS Excl Extra (Annual)$-3.74
CapEx CAGR (5Y)-11.13%
Tangible BV CAGR (5Y)-13.41%
26-Week Price Return33.15%
Quick Ratio (Annual)2.19x
13-Week Price Return-1.89%
Total Debt / Equity (Annual)0.02x
Current Ratio (Quarterly)2.39x
Enterprise Value$344.364
Revenue / Share Growth (5Y)-4.00%
Asset Turnover (TTM)0.37x
Book Value / Share Growth (5Y)-7.68%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)7.29x
Pretax Margin (Annual)-64.16%
Cash / Share (Annual)$4.46
3-Month Return Std Dev110.59%
Gross Margin (5Y Avg)92.30%
Net Income / Employee (TTM)$-0
ROE (Last FY)-67.38%
EPS Basic Excl Extra (Annual)$-3.74
P/FCF (TTM)55.77x
Receivables Turnover (TTM)4.25x
EV / Free Cash Flow (TTM)-20.52x
Total Debt / Equity (Quarterly)0.02x
EPS Incl Extra (TTM)$-3.74
Receivables Turnover (Annual)4.25x
ROI (TTM)-48.62%
P/S Ratio (TTM)1.95x
Pretax Margin (5Y Avg)-10.44%
Revenue / Share (Annual)$3.67
Tangible BV / Share (Annual)$3.55
Price vs S&P 500 (52W)36.91%
Year-to-Date Return-17.57%
5-Day Price Return-0.82%
EPS Normalized (Annual)$-3.74
ROA (5Y Avg)-8.20%
Net Profit Margin (Annual)-102.02%
Month-to-Date Return5.21%
Cash Flow / Share (TTM)$0.25
EBITD / Share (Annual)$-2.23
Operating Margin (Annual)-69.95%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-12.23%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-3.74
P/TBV (Quarterly)2.48x
P/B Ratio (Annual)1.59x
Inventory Turnover (TTM)7.29x
Pretax Margin (TTM)-64.16%
Book Value / Share (Annual)$5.54
Price vs S&P 500 (13W)-2.58%
Beta0.67x
P/FCF (Annual)33.96x
Revenue / Share (TTM)$3.66
ROE (TTM)-49.24%
52-Week Low$3.81
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
VNDAVanda Pharmaceuticals Inc. | 1.95x | 8.72% | 93.96% | — | $7.16 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Vanda Pharmaceuticals is a biopharmaceutical company developing therapies for neurology and psychiatry conditions with significant unmet medical needs. Its commercial portfolio includes HETLIOZ (for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis Syndrome), Fanapt (schizophrenia), and PONVORY, with Fanapt generating the majority of revenue. The company operates primarily in the United States, with additional markets in Europe, Israel, and Canada, and maintains a pipeline of development-stage candidates.